Continuous Provision of Medical Care
First written in FY2019. 5 of 9 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2026.
Qol Holdings moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The group has set its vision for 2030 as “Becoming an entity that delivers peace of mind in healthcare to everyone,” along with targets for the fiscal year ending March 2031 of consolidated revenue of ¥500 billion, operating profit of ¥35 billion, and ROE of 15%. To achieve these targets, the group has adopted “深化と進化” as its basic policy and will realize the development and growth of its pharmacy, BPO, and pharmaceutical businesses.」
The company is linking its longstanding goal of providing continuity of medical care with its long-term vision of delivering peace of mind in healthcare in 2030 and developing its 3 businesses. - FY2023-Q2RestatedAnnual report
「The company will celebrate its 30th anniversary this year. It has continued its business based on the belief in continuity of healthcare, aiming to operate community-based pharmacies. Going forward, under the group's corporate philosophy, “We are committed to the quality of life of everyone, anytime and anywhere, for you,” it will continue moving forward as a comprehensive healthcare company.」
Even at the milestone of its 30th anniversary, the company continues to pursue its goal of community-based pharmacies, continuity of medical care, and advancement toward becoming an integrated healthcare company. - FY2023-Q1RestatedAnnual report
「The company will celebrate its 30th anniversary this year. It has continued its business based on the belief in continuity of healthcare, aiming to operate community-based pharmacies. Going forward, under the group's corporate philosophy, “We are committed to the quality of life of everyone, anytime and anywhere, for you,” it will continue moving forward as a comprehensive healthcare company.」
The company reaffirmed its business policy based on a commitment to community-based pharmacies and continuity of medical care, and has set out to advance toward becoming an integrated healthcare company. - FY2022AdvancedAnnual report
「In the health insurance pharmacy business, we are pursuing active M&A and new store openings, as well as promoting home and institutional dispensing as a new business pillar, thereby establishing a system that contributes to the stabilization of regional healthcare and improved patient convenience.」
The company is developing a structure that combines M&A and new openings with home-care and institutional dispensing, toward providing continuity of medical care. - FY2021AdvancedAnnual report
「By actively opening new locations and pursuing M&A, the company will promote continuity and consistency in the quality of medical care, build a structure that can contribute more than ever to stabilizing community healthcare and improving patient convenience, and seek to enhance corporate value through the exchange of talented personnel across the organization.」
The company outlined a structure linking new openings and M&A with consistency in the quality of medical care and the stabilization of community healthcare, toward providing continuity of medical care. - FY2020-Q3AdvancedAnnual report
「Going forward, the group will enhance synergies among its 3 businesses, establish an end-to-end service spanning pharmaceutical manufacturing through delivery to patients, and pursue its goal of becoming a comprehensive healthcare company.」
The company clearly outlined a direction of increasing synergies among its 3 businesses and establishing an end-to-end service to provide continuity of medical care. - FY2020-Q2AdvancedAnnual report
「As an important business strategy for achieving its medium-term targets, the group planned the pharmaceutical manufacturing and sales business as a third business following the dispensing pharmacy and BPO businesses. As the first step toward entering and expanding this business, it acquired all shares of Fujinaga Pharmaceutical Co., Ltd. on 8 August 2019.」
As the first specific step in its plan for a third business aimed at providing continuity of medical care, the company acquired all shares of 藤永製薬株式会社. - FY2020-Q1AdvancedAnnual report
「As an important business strategy for achieving its medium-term targets, the Group plans to make the pharmaceutical manufacturing and marketing business its third business, following the existing BPO business and centered on its insurance pharmacy business. As the first step toward entering and expanding the pharmaceutical manufacturing and marketing business, the Group will acquire all shares of 藤永製薬株式会社, as described in the “Notice Regarding the Acquisition of Shares in 藤永製薬株式会社 (Making It a Subsidiary)” announced on 31 July 2019.」
Regarding the creation of a third business, the company outlined the specific first steps of entering the pharmaceutical manufacturing and marketing business and acquiring all shares of 藤永製薬株式会社. - FY2019First statedAnnual report
「Our group has identified “providing continuous healthcare” as a key challenge. As part of its medium- to long-term management strategy, in addition to growing its two core businesses, the insurance pharmacy business and the BPO business, it is advancing plans for new businesses with strong synergies with its existing operations in order to create a third core business.」
The company identified “continuity of medical care” as a key issue and outlined a policy to grow its 2 existing businesses while advancing plans for a new business to become its third pillar.